Overview

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Eligibility

Inclusion Criteria:

• Participants must be ≥ 18 years of age.
• Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
• Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.
• For Part 2A only, participants must have CCNE1-amplified ovarian cancer

Exclusion Criteria:

• Participants must not have an active brain metastasis.
• Participants must not have impaired cardiac function or clinically significant cardiac disease.
• Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
• Participants must not have Grade ≥ 2 peripheral neuropathy.
• Other protocol-defined Inclusion/Exclusion criteria apply.